Eton Net Income From Continuing Ops from 2010 to 2024

ETON Stock  USD 11.82  0.64  5.14%   
Eton Pharmaceuticals Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -982.8 K. During the period from 2010 to 2024, Eton Pharmaceuticals Net Loss quarterly data regression pattern had range of 27 M and standard deviation of  6,703,169. View All Fundamentals
 
Net Loss  
First Reported
2017-06-30
Previous Quarter
-3 M
Current Value
627 K
Quarterly Volatility
3.3 M
 
Covid
Check Eton Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eton Pharmaceuticals' main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 596.8 K or Selling General Administrative of 12.9 M, as well as many indicators such as Price To Sales Ratio of 3.37, Dividend Yield of 0.0214 or PTB Ratio of 8.23. Eton financial statements analysis is a perfect complement when working with Eton Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.

Latest Eton Pharmaceuticals' Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Eton Pharmaceuticals over the last few years. It is Eton Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eton Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Pretty Stable
   Net Income From Continuing Ops   
       Timeline  

Eton Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(10,519,787)
Coefficient Of Variation(63.72)
Mean Deviation3,891,246
Median(10,734,000)
Standard Deviation6,703,169
Sample Variance44.9T
Range27M
R-Value0.24
Mean Square Error45.5T
R-Squared0.06
Significance0.38
Slope363,719
Total Sum of Squares629.1T

Eton Net Income From Continuing Ops History

2024-982.8 K
2023-936 K
2022-9 M
2021-2 M
2020-28 M
2019-18.3 M
2018-12.7 M

About Eton Pharmaceuticals Financial Statements

Eton Pharmaceuticals investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Eton Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-936 K-982.8 K

Pair Trading with Eton Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eton Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Eton Stock

  0.79EPIX ESSA Pharma Earnings Call This WeekPairCorr
  0.76EYEN EyenoviaPairCorr
  0.76FATE Fate TherapeuticsPairCorr
  0.75VRCA Verrica PharmaceuticalsPairCorr
  0.74ENVB Enveric BiosciencesPairCorr
The ability to find closely correlated positions to Eton Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eton Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eton Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eton Pharmaceuticals to buy it.
The correlation of Eton Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eton Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eton Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eton Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Eton Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eton Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eton Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eton Pharmaceuticals Stock:
Check out the analysis of Eton Pharmaceuticals Correlation against competitors.
To learn how to invest in Eton Stock, please use our How to Invest in Eton Pharmaceuticals guide.
You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eton Pharmaceuticals. If investors know Eton will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eton Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Earnings Share
(0.26)
Revenue Per Share
1.219
Quarterly Revenue Growth
(0.24)
Return On Assets
(0.12)
The market value of Eton Pharmaceuticals is measured differently than its book value, which is the value of Eton that is recorded on the company's balance sheet. Investors also form their own opinion of Eton Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eton Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eton Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eton Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eton Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eton Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eton Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.